Bruker (NASDAQ:BRKR) PT Set at $43.00 by Barclays

Key Points

• Barclays lowered Bruker's price target from $46.00 to $43.00, indicating a potential upside of 23.85% based on the current stock price.
• Bruker reported $0.32 EPS, below the consensus estimate of $0.43, alongside a revenue of $797.4 million, slightly under the $811.17 million estimate.
• Institutional investors now hold 79.52% of Bruker's stock, with significant increases from hedge funds like London Co. of Virginia and Sculptor Capital LP.

Bruker (NASDAQ:BRKR - Get Free Report) has been given a $43.00 price objective by analysts at Barclays in a research report issued to clients and investors on Monday, MarketBeat reports. The firm presently has an "overweight" rating on the medical research company's stock. Barclays's price objective suggests a potential upside of 37.89% from the stock's current price.

Other research analysts have also issued reports about the stock. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the company a "buy" rating in a report on Monday. Stifel Nicolaus reduced their target price on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Wells Fargo & Company reduced their target price on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. UBS Group reduced their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group reduced their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Bruker currently has an average rating of "Hold" and an average price target of $51.30.

Bruker Stock Down 2.8%

Shares of BRKR traded down $0.89 during midday trading on Monday, hitting $31.19. The company had a trading volume of 325,754 shares, compared to its average volume of 2,394,168. The company's 50 day moving average price is $39.83 and its 200 day moving average price is $43.12. The stock has a market cap of $4.73 billion, a price-to-earnings ratio of 59.46, a PEG ratio of 2.34 and a beta of 1.16. Bruker has a 52 week low of $30.74 and a 52 week high of $72.94. The company has a quick ratio of 0.74, a current ratio of 1.61 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same period last year, the firm posted $0.52 earnings per share. The company's quarterly revenue was down .4% on a year-over-year basis. On average, equities research analysts predict that Bruker will post 2.69 EPS for the current year.

Insider Activity at Bruker

In other Bruker news, CEO Frank H. Laukien bought 2,608 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were acquired at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the acquisition, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 27.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Bruker

A number of large investors have recently made changes to their positions in the company. Huntington National Bank raised its holdings in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock valued at $30,000 after acquiring an additional 645 shares during the period. Bank of Montreal Can grew its position in Bruker by 4.4% in the second quarter. Bank of Montreal Can now owns 21,262 shares of the medical research company's stock worth $876,000 after acquiring an additional 894 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Bruker by 33.6% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,788 shares of the medical research company's stock worth $280,000 after buying an additional 1,706 shares during the period. Buckhead Capital Management LLC boosted its holdings in shares of Bruker by 74.2% during the 2nd quarter. Buckhead Capital Management LLC now owns 59,348 shares of the medical research company's stock worth $2,445,000 after buying an additional 25,288 shares during the period. Finally, Retirement Systems of Alabama boosted its holdings in shares of Bruker by 0.4% during the 2nd quarter. Retirement Systems of Alabama now owns 135,201 shares of the medical research company's stock worth $5,570,000 after buying an additional 506 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.